Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer

Basit Öğe Kaydı
dc.contributor.authorTopcu, Atakan
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorSecmeler, Saban
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorAyhan, Murat
dc.contributor.authorOzkan, Metin
dc.contributor.authorBozkurt, Oktay
dc.date.accessioned2024-04-24T17:18:40Z
dc.date.available2024-04-24T17:18:40Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractGastric cancer has a poor prognosis despite available treatments. Inclusive studies are still needed with real-life data. Our research retrospectively evaluated the efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer who received trastuzumab-based chemotherapy as first-line therapy. In total, 138 patients were included in this study. Clinical response to trastuzumab-based chemotherapy was obtained in 79% of the patients. We also divided the patients who had a clinical response into two groups according to whether they received maintenance therapy. In the present study, trastuzumab administration had compatible survival outcomes with recent studies. Continuation of trastuzumab maintenance treatment provided a survival advantage in patients with clinical response. We suppose that maintenance trastuzumab may be recommended in patients with clinical responses to the first-line treatment. Furthermore, Eastern Cooperative Oncology Group Performance Status 2, grade 3 and having more than four metastatic lesions were determined as risk factors for death. Therefore, although we recommend maintenance of trastuzumab in patients with clinical response, those with identified risk factors may not benefit from treatment. Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 patients who were given trastuzumab-based chemotherapy as first-line treatment and analyzed the relationship between clinical response rates and maintenance treatment status and survival outcomes. Results: In the whole group, the median progression-free survival and overall survival were 10.2 and 16 months, respectively. Clinical response was obtained in 79% of patients. The median overall survival was 16.9 months in follow-up group and 19.0 months in the maintenance group in patients with clinical response. Continuation of maintenance trastuzumab created a significant survival advantage (p = 0.021). Eastern Cooperative Oncology Group performance status 2 (hazard ratio [HR]: 2.02), grade 3 (HR: 1.78) and more than four metastatic lesions (HR: 1.67) were determined as risk factors for death. Conclusion: We recommend the continuation of maintenance trastuzumab in patients with clinical response, but those with identified risk factors may not benefit from treatment because life expectancy may be low.en_US
dc.identifier.doi10.2217/fon-2021-0398
dc.identifier.endpage4169en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue31en_US
dc.identifier.pmid34323116
dc.identifier.scopus2-s2.0-85117942646
dc.identifier.scopusqualityQ2
dc.identifier.startpage4157en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2021-0398
dc.identifier.urihttps://hdl.handle.net/11468/18866
dc.identifier.volume17en_US
dc.identifier.wosWOS:000678735400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectClinical Responseen_US
dc.subjectEfficacyen_US
dc.subjectFirst-Line Treatmenten_US
dc.subjectGastric Canceren_US
dc.subjectHer2en_US
dc.subjectMaintenanceen_US
dc.subjectReal-Life Dataen_US
dc.subjectRisk Factoren_US
dc.subjectTrastuzumaben_US
dc.titleEfficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric canceren_US
dc.titleEfficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu